EN | RU
EN | RU

Help Support

Back

Price of pain: population-based cohort burden of disease analysis of medication cost of herpes zoster and postherpetic neuralgia

Price of pain: population-based cohort burden of disease analysis of medication cost of herpes zoster and postherpetic neuralgia Price of pain: population-based cohort burden of disease analysis of medication cost of herpes zoster and postherpetic neuralgia
Price of pain: population-based cohort burden of disease analysis of medication cost of herpes zoster and postherpetic neuralgia Price of pain: population-based cohort burden of disease analysis of medication cost of herpes zoster and postherpetic neuralgia

Pain is a main symptom of herpes zoster (HZ), and postherpetic neuralgia (PHN) is a frequent complication occurring in 5% to 15% of cases, causing moderate to severe neuropathic pain.

See All

Key take away

Postherpetic neuralgia is a complication of shingles affecting nerve fibers and skin, inducing burning pain that lasts long after the rash and blisters of shingles vanish. The cost issues related to the use of gabapentin have been discussed appropriately in this study.

Background

Pain is a main symptom of herpes zoster (HZ), and postherpetic neuralgia (PHN) is a frequent complication occurring in 5% to 15% of cases, causing moderate to severe neuropathic pain. A population-based observational study was conducted to evaluate the treatment patterns and economic burden of prescription drug treatment of HZ and PHN pain in the province of Manitoba (Canada) over a period of 15 years.

Method

Administrative health care data, including medical and hospital separation records, were examined to identify episodes of HZ using International Classification of Diseases-9/10 codes between April 1, 1997 and March 31, 2014. Episodes of PHN were identified using medical and prescription claims. Incident use of analgesic, antidepressant, or anticonvulsant drugs was used to determine prescription pain costs.

Result

The age-adjusted incidence of HZ increased from 4.7 episodes/1,000 person-years in 1997/98 to 5.7/1,000 person-years in 2013/14. PHN occurred in 9.2% of HZ cases, a rate that did not change over the study period (P=0.57). The annual cost to treat HZ pain rose by 174% from 1997/98, reaching CAD $332,981 in 2011/12, 82.8% (95% confidence interval [CI] 81.2%, 84.3%) of which was related to PHN. The per episode cost of HZ rose by 111% from $31.59 (95% CI $25.35, $37.84) to $66.81 (95% CI $56.84, $76.78) and by 94% for PHN from $292 (95% CI $225, $358) to $566 (95% CI $478, $655). These increases were driven by increasing use of anticonvulsants, primarily gabapentin, which accounted for 57% of the increase in cost.

Conclusion

There has been an increase in the incidence of HZ and PHN and in the average cost associated with the prescription treatment of their resultant neuropathic pain. The primary driver of the increased episodic cost is the increased use of gabapentin. These changes have resulted in a substantial increase in the economic burden associated with HZ and PHN.

Source:

Journal of Pain Research

Article:

Price of pain: population-based cohort burden of disease analysis of medication cost of herpes zoster and postherpetic neuralgia

Authors:

Friesen KJ et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en
Try: